- Potentially best-in-class monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis
- Engineered for extended circulation times while meeting or exceeding the performance and safety profiles of existing IL-23p19–targeted approaches
- Potential to enable dosing as infrequently as once or twice a year
MoA animation
made by Visual Science, 2026
Therapeutics that enable life, uninterrupted
At Oruka, we apply state-of-the-art antibody engineering to validated modes of action to develop biologics with the potential to redefine the standard of care for psoriasis, psoriatic arthritis, hidradenitis suppurativa, and other indications.
Our lead programs, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19) and ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F). We have optimized ORKA-001 and ORKA-002 with the aim of perfecting the product profile we can offer and enabling patients to experience the greatest possible freedom from disease.
High-impact therapies that build on proven approaches
Our programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety. They incorporate advanced antibody engineering, including half-life extension technology, to extend dosing intervals and potentially deliver best-in-class performance.
PROGRAM
Preclinical
Phase 1
Phase 2
Potential indications
ORKA-001
Psoriasis
ORKA-002
Psoriasis, hidradenitis suppurativa, psoriatic arthritis, others
- Potentially best-in-class monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions
- Engineered for extended circulation times while meeting or exceeding the performance and safety profiles of existing IL-17A/F–targeted approaches
- Potential to enable dosing as infrequently as two or three times a year
ORKA-004
- Novel half-life extended monoclonal antibody designed to inhibit TL1A, to be pursued in combination with ORKA-001 and ORKA-002
ORKA-003
Learn more about participating in our clinical trials
Presentations and Publications
AAD 2026
ORKA-002: Phase 1 Data
Phase 1 Clinical Trial of ORKA-002, a Novel Half-Life Extended IL-17A/F Monoclonal Antibody with Potential for Twice Yearly Dosing in...
EADV 2025
ORKA-001: Phase 1 Data
Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque...
EADV 2025
ORKA-001: EVERLAST-A Phase 2a Study Design
EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis
AAD 2025
ORKA-002: Product Characterization
Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
EADV 2024
ORKA-001: Product Characterization
ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 with the Potential to Improve upon Currently Available Therapies for Psoriasis